Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees. On June 1, 2026, 17 newly hired non-executive employees received options to purchase an aggregate of 513,500 shares under the 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4).

The options have a $1.22 per share exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly, subject to continuous service.

Positive

• 513,500 stock options granted to support 17 new hires
• Exercise price set at $1.22, aligned with grant date close
• Four-year vesting schedule supports employee retention
• 10-year option term offers long-dated equity incentive

Negative

• Potential future dilution from 513,500 additional option shares

News Market Reaction – IVVD

-3.51%

7 alerts

-3.51% Session close to close

+2.0% Peak in 5 min

$344.43M Market Cap

0.1x Rel. Volume

In the Jun 3 session, IVVD declined 3.51%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock option grants covering 513,500 shares for 17 new employee...

Analysis

This announcement details inducement stock option grants covering 513,500 shares for 17 new employees under Nasdaq Listing Rule 5635(c)(4), with a $1.22 exercise price, four-year vesting, and a 10-year term. It adds incremental equity overhang but is typical for recruiting. Set against recent Phase 3 trial progress, widening losses, and an active Form S-3 shelf, investors may track total equity-based compensation and any further use of registered financing when evaluating future dilution.

Key Figures

New hires granted: 17 employees Option shares granted: 513,500 shares Exercise price: $1.22 per share +5 more

8 metrics

New hires granted 17 employees Non-executive employees receiving inducement stock options

Option shares granted 513,500 shares Aggregate common stock underlying inducement options

Exercise price $1.22 per share Closing price on June 1, 2026 grant date

Vesting period 4 years Employee stock option vesting schedule

Initial vesting 25% at 1 year Cliff vesting on first anniversary of start date

Option term 10 years Contractual life of inducement stock options

Current share price $1.14 Pre-news trading level vs $1.22 option strike

52-week range $0.483–$3.0699 IVVD 52-week low and high before this filing

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Phase 3 enrollment	Positive	+7.0%	Completed enrollment in upsized Phase 3 DECLARATION trial for VYD2311.
May 27	Investor conferences	Positive	+2.7%	Announced participation in multiple June 2026 investor events and webcasts.
May 14	Earnings results	Negative	-21.1%	Reported higher revenue but a $41.4M net loss and increased spending.
May 11	Clinical analysis	Positive	+0.7%	Shared new tolerability analysis for COVID-19 mAb versus vaccines in EVADE/COMPARE.
May 07	Earnings call notice	Neutral	-2.0%	Announced scheduling of Q1 2026 financial results and corporate update call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

IVVD has generally moved in the same direction as the perceived sentiment of prior news, with only one recent divergence on a neutral event.

Recent Company History

Over the last month, Invivyd has reported several clinically and strategically important updates. Completion of enrollment in the upsized Phase 3 DECLARATION trial for VYD2311 on Jun 01 saw a 7.02% gain, while participation in June investor conferences on May 27 aligned with a 2.73% rise. Q1 2026 results on May 14, highlighting a $41.4 million net loss, coincided with a -21.09% drop. Scientific communication around COVID-19 antibodies and routine earnings-call scheduling produced modest or mixed reactions. Today’s inducement option grants fit into this pattern of steady operational disclosures.

Key Terms

nasdaq listing rule 5635(c)(4), stock options

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"employees options to purchase an aggregate of 513,500 shares of its common stock"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.22, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd  

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

What inducement stock options did Invivyd (IVVD) grant on June 1, 2026?

Invivyd granted options to purchase an aggregate of 513,500 common shares to 17 newly hired non-executive employees. According to Invivyd, these awards were issued as material inducements to accept employment.

What is the exercise price of the June 2026 Invivyd (IVVD) inducement options?

The inducement options have an exercise price of $1.22 per share. According to Invivyd, this price equals the closing price of its common stock on the June 1, 2026 grant date.

How do Invivyd (IVVD) June 2026 inducement options vest for new employees?

Each option vests over four years, with 25% of shares vesting on the first anniversary of the employee’s start date. According to Invivyd, the remaining shares vest in equal monthly installments, subject to continuous service.

Under which plan were the Invivyd (IVVD) June 2026 inducement grants issued?

The options were granted under the Invivyd 2026 Inducement Plan. According to Invivyd, these awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducement grants.

What is the term of the Invivyd (IVVD) inducement stock options granted in June 2026?

The inducement stock options have a 10-year term from the grant date. According to Invivyd, the options remain subject to the terms and conditions of the 2026 Inducement Plan.